Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) Paris, France – April 25 th , 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform , today announced that clinical data from the ongoing Phase 1/2 trial of EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) will be presented at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 31 – June 4, in Chicago, Illinois. Poster presentation details – Abstract 7058 Title : Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY) Presenting Author : J.C. C. Villasboas Bisneto, M.D., Mayo Clinic Session Name: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Session Date and Time: June 3 rd , 9:00 AM-12:00 PM CDT SIDNEY (EONHL1-20) is a Phase 1/2 multicenter, open-label, first-in-human study of EO2463 as monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with indolent non-Hodgkin lymphoma (NHL). The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL). For more information on the study, refer to Clinicaltrials.gov identifier: NCT04669171. About EO2463: EO2463 is an innovative, off-the-shelf immunotherapy candidate that combines four synthetic OncoMimic™ peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). EO2463 also includes the helper peptide (CD4 + epitope) universal cancer peptide 2 (UCP2). The unique ability of EO2463 immunotherapy to selectively target multiple B cell markers enables the destruction of malignant B lymphocytes that are abundant in iNHL. By ensuring broad target coverage across malignant B cells while avoiding a detrimental impact on normal peripheral B cells, this novel approach aims to simultaneously improve safety and maximize efficacy, reducing the tumor cells’ capacity to develop immune escape mechanisms. Download the press release (.pdf format) Enterome Headquarters 94/96 avenue Ledru-Rollin 75011 Paris – France Tel: +33 (0)1 75 77 27 85 Email: [email protected] Metro Station: Ledru-Rollin (Line 8) About About us Leadership Investors Pipeline Pipeline OncoMimics™ Platform Our Mimicry Approach Our Drug Discovery Platform Clinical Trials B cell malignancies Glioblastoma Adrenal tumors Colorectal Cancer News & Events Press Releases Press Coverage Webinars Presentations & Posters Relevant Literature Careers Our Values Careers Cookies Policy Privacy Policy Legal Notice

The release as fetched from its publisher. enterome.com ↗